Alpha 2.0
Login Register
» Articles » PMID: 32400364

Evaluation of Commercial and Automated SARS-CoV-2 IgG and IgA ELISAs Using Coronavirus Disease (COVID-19) Patient Samples

Overview
Journal Euro Surveill
Specialty Infectious Diseases
Date 2020 May 14
PMID 32400364
Citations 68
Authors
Anne J Jaaskelainen
Eliisa Kekalainen
Hannimari Kallio-Kokko
Laura Mannonen
Elisa Kortela
Olli Vapalahti
Satu Kurkela
Maija Lappalainen
Affiliations
Soon will be listed here.
Abstract

Antibody-screening methods to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) need to be validated. We evaluated SARS-CoV-2 IgG and IgA ELISAs in conjunction with the EUROLabworkstation (Euroimmun, Lübeck, Germany). Overall specificities were 91.9% and 73.0% for IgG and IgA ELISAs, respectively. Of 39 coronavirus disease patients, 13 were IgG and IgA positive and 11 IgA alone at sampling. IgGs and IgAs were respectively detected at a median of 12 and 11 days after symptom onset.

Citing Articles

Detection methods and dynamic characteristics of specific antibodies in patients with COVID-19: A review of the early literature.

Xu J, Chen J, Wen F, Liu K, Chen Y Heliyon. 2024; 10(3):e24580.

PMID: 38317938 PMC: 10839880. DOI: 10.1016/j.heliyon.2024.e24580.

Performance estimation of two in-house ELISA assays for COVID-19 surveillance through the combined detection of anti-SARS-CoV-2 IgA, IgM, and IgG immunoglobulin isotypes.

Ramirez-Reveco A, Velasquez G, Aros C, Navarrete G, Villarroel-Espindola F, Navarrete M PLoS One. 2023; 18(2):e0270388.

PMID: 36745590 PMC: 9901778. DOI: 10.1371/journal.pone.0270388.

Development of in House ELISAs to Detect Antibodies to SARS-CoV-2 in Infected and Vaccinated Humans by Using Recombinant S, S1 and RBD Proteins.

Yilmaz A, Turan N, Kocazeybek B, Oyku Dinc H, Tali H, Aydin O Diagnostics (Basel). 2022; 12(12).

PMID: 36553092 PMC: 9777145. DOI: 10.3390/diagnostics12123085.

Antibody tests for identification of current and past infection with SARS-CoV-2.

Fox T, Geppert J, Dinnes J, Scandrett K, Bigio J, Sulis G Cochrane Database Syst Rev. 2022; 11():CD013652.

PMID: 36394900 PMC: 9671206. DOI: 10.1002/14651858.CD013652.pub2.

Kinetics of severe acute respiratory syndrome coronavirus 2 infection antibody responses.

Lin Y, Zhu J, Liu Z, Li C, Guo Y, Wang Y Front Immunol. 2022; 13:864278.

PMID: 35990623 PMC: 9389018. DOI: 10.3389/fimmu.2022.864278.

References
1.
Okba N, Raj V, Widjaja I, GeurtsvanKessel C, de Bruin E, Chandler F . Sensitive and Specific Detection of Low-Level Antibody Responses in Mild Middle East Respiratory Syndrome Coronavirus Infections. Emerg Infect Dis. 2019; 25(10):1868-1877. PMC: 6759241. DOI: 10.3201/eid2510.190051. View
2.
Corman V, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu D . Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020; 25(3). PMC: 6988269. DOI: 10.2807/1560-7917.ES.2020.25.3.2000045. View
3.
Amanat F, Stadlbauer D, Strohmeier S, Nguyen T, Chromikova V, McMahon M . A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat Med. 2020; 26(7):1033-1036. PMC: 8183627. DOI: 10.1038/s41591-020-0913-5. View
4.
Spiteri G, Fielding J, Diercke M, Campese C, Enouf V, Gaymard A . First cases of coronavirus disease 2019 (COVID-19) in the WHO European Region, 24 January to 21 February 2020. Euro Surveill. 2020; 25(9). PMC: 7068164. DOI: 10.2807/1560-7917.ES.2020.25.9.2000178. View
5.
Nicastri E, DAbramo A, Faggioni G, De Santis R, Mariano A, Lepore L . Coronavirus disease (COVID-19) in a paucisymptomatic patient: epidemiological and clinical challenge in settings with limited community transmission, Italy, February 2020. Euro Surveill. 2020; 25(11). PMC: 7096776. DOI: 10.2807/1560-7917.ES.2020.25.11.2000230. View